One molecule, two receptors
The obesity field has learned that stacking hormones beats using one, and it has two ways to do it: combine separate…
The single-molecule strategy
The obesity field has learned that stacking hormones beats using one, and it has two ways to do it: combine separate drugs, or engineer one molecule that hits several receptors. Amycretin is the single-molecule, or unimolecular, approach applied to the GLP-1 plus amylin pairing.
This unit explains what a unimolecular co-agonist is, why amycretin is a genuine first for the GLP-1 plus amylin combination, and the honest trade-off hidden in a fixed single-molecule ratio.
Key terms
How a co-agonist is built
A unimolecular co-agonist is one peptide engineered to activate more than one receptor. Amycretin applies the idea to the GLP-1 plus amylin pairing: a single chain carrying a GLP-1 part and an amylin part, joined by a short linker, which in cell assays activated human, mouse and rat GLP-1, amylin and calcitonin receptors.
Each step is a real hurdle. Getting both receptors activated by one chain, at a sensible balance, while keeping the molecule stable and long-lasting, is genuinely hard chemistry. That difficulty is why a single-molecule GLP-1 plus amylin agonist is notable: the two-drug combination proved the biology, but the fusion is a distinct engineering achievement.
AdvancedWhy fusion is harder than mixing
Mixing two finished drugs (like CagriSema) lets each be optimized separately. A fusion must satisfy competing constraints in one molecule: the shape that binds the GLP-1 receptor, the shape that binds the amylin receptor, resistance to enzymes, and albumin binding, all at once. A change that helps one property can hurt another, so the design space is far tighter than for a simple co-formulation.